[1/2] Boxes of the drug trulicity, made by Eli Lilly and Company, sit on a counter at a pharmacy in Provo, Utah, U.S. January 9, 2020.
REUTERS/George FreyDec 16 (Reuters) - The U.S. health regulator has added Eli Lilly and Co's (LLY.N) Mounjaro to its list of drugs facing shortages, highlighting the company's struggles to meet booming demand for the newly approved diabetes injection.
Trulicity, another diabetes treatment in the company's stable and its biggest-selling drug, was also added to the Food and Drug Administration's shortage list on Thursday.
The company anticipates the drug, which has the common name tirzepatide, to get nod for obesity, an even bigger market, next year.
Supply problems have also plagued a rival obesity drug, Wegovy, from Novo Nordisk (NOVOb.CO), although the Danish drugmaker is also working on boosting manufacturing capacity.